2. Nanda R, Liu MC,Yau C, et al. Effect of Pembrolizumab Plus NeoadjuvantChemotherapy on Pathologic Complete Response in Women With Early-Stage BreastCancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Onco...
Holmes FA, Patt D, Manalo Y, et al. Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. Canc...
2. Nanda R, Liu MC,Yau C, et al. Effect of Pembrolizumab Plus NeoadjuvantChemotherapy on Pathologic Complete Response in Women With Early-Stage BreastCancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Oncol.2020 May 1;6(5):676-684. 3.I-SPY2 Trial Consortiu...
[17]Ismael G, Hegg R, et al.Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78. [18]Jackis...
1、Peter Schmid, et al.Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study. 2023 SABCS abstract #LBO1-01. ...
[6]Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer.N Engl J Med.2015 Jan 8;372(2):134-41. [7]MDACC.Breast cancer–invasive stage I-III algorithm.https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians...
参考文献: Marra, Antonio et al. “Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.” Nature reviews. Clinical oncology vol. 21,3 (2024): 185-202. doi:10.1038/s41571-023-00849-9...
帕博利珠单抗联合新辅助化疗,以及后续联合辅助内分泌治疗早期高危ER+/HER2-乳腺癌:3期KEYNOTE-756研究 讲者:Javier Cortes 摘要号:6 Adjuvant Hypofractionated Whole Breast lrradiation (WB) Versus Accelerated Partial Breast lrradiationAPB) in Postmenopausal Women with Early Stage Breast Cancer: 5-Years Update...
近日，来自美国耶鲁大学的Lajos Pusztai团队在Cancer Cell上在线发表题为Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial 的文章，报道了一项用于II/III期早期乳腺癌的I-SPY2试验结果，显示度伐利尤与奥拉帕尼...
[4]Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial. | Journal of Clinical Oncology ...